China appears to have beaten the world to a bird flu vaccine Scientists in China have developed a potential vaccine against the deadly H5N1 bird flu virus currently sweeping across Asia. The vaccine offers raised expectations for the rapid security of thousands of people should the virus mutate right into a pandemic form. The vaccine is made up of an inactivated sample of the existing H5N1 avian flu virus with the addition of an adjuvant that enhances the immune response. In trials of the vaccine on 120 volunteers it produced an excellent immune response and perhaps has the potential to become mass produced in an emergency to provide safety for 675 million people. The volunteers aged between 18 and 60 received either a dummy method or the vaccine at dosages of 1 1.25, 2.5, 5 and 10 micrograms with aluminium hydroxide as the adjuvant.13, 2010. Poster presenters must attend the session and be open to discuss their study. Related StoriesJEDI T-cells provide unique technology to review, visualize immune immunotherapiesAstellas and responses enters into definitive agreement to acquire OcataFirst patient of U.S. The deadline for submitting poster abstracts can be Sept. 8, 2010. Idea leaders from the biotechnology market, academia, and science community are invited to post proposals for the following program tracks: Renewable Chemicals & Biobased Polymers Biofuels & Bioenergy Platforms Algae Production Systems & Marine Biotechnology Specialty Crops, Renewable Feedstocks, & Sustainability Synthetic Biology and Metabolic Engineering Right now in its fifth yr, the Pacific Rim Summit on Industrial Bioenergy and Biotechnology will address the most recent issues in commercial biotechnology, including algae, advanced biofuels, biopolymers and bioplastics, devoted energy crops, green chemistry, and artificial biology.